Regeneron Pharmaceuticals
REGN
925 hedge funds and large institutions have $42.4B invested in Regeneron Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 137 funds opening new positions, 384 increasing their positions, 287 reducing their positions, and 111 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 384 | Existing positions reduced: 287
23% more first-time investments, than exits
New positions opened: 137 | Existing positions closed: 111
21% more funds holding in top 10
Funds holding in top 10: 14 → 17 (+3)
2% more funds holding
Funds holding: 904 → 925 (+21)
4% less capital invested
Capital invested by funds: $44.3B → $42.4B (-$1.94B)
1.09% less ownership
Funds ownership: 86.35% → 85.26% (-1.1%)
33% less call options, than puts
Call options by funds: $917M | Put options by funds: $1.38B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$374M |
| 2 |
JP Morgan Chase
New York
|
+$351M |
| 3 |
Harris Associates
Chicago,
Illinois
|
+$246M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$161M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$154M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polen Capital Management
Boca Raton,
Florida
|
-$968M |
| 2 |
Renaissance Technologies
New York
|
-$409M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$371M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$266M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$243M |
REGN Hedge Fund Activity: Q1 2021 in Review
925 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2021, worth a combined $42.4B — down 4.4% from $44.3B a quarter earlier.
Buyers outnumbered sellers: 137 funds opened new REGN positions and 111 closed out — a net gain of 26 holders — while 384 added to existing stakes and 287 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $374M. The largest seller was Polen Capital Management, exiting entirely with an estimated $968M sold.
- 925 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2021, up from 904 in Q4 2020.
- Funds reported $42.4B of Regeneron Pharmaceuticals stock for Q1 2021, down 4.4% quarter-over-quarter.
- 137 funds opened new Regeneron Pharmaceuticals positions in Q1 2021 and 111 closed out, a net change of +26 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2021 was ARK Investment Management, an estimated $374M added.
- The largest Regeneron Pharmaceuticals seller in Q1 2021 was Polen Capital Management, an estimated $968M sold.
Based on aggregated 13F filings for Q1 2021.